EVAL. OF HUMAN ANTICOLORECTAL CARCINOMA MOAB IN PATS. WITH DISSEM. COLON CA

大量的患者已经用鼠 单克隆抗体在几个阶段I和II研究。 总的来说， 这种疗法的抗肿瘤效果令人惊讶， 几个 然而，已经证明，抗体可以 到达肿瘤部位并特异性地对肿瘤细胞进行应变。 一般来说，似乎单克隆抗体在和 目前正在使用的工具本身并不是有效的工具， 癌症的治疗。 使用鼠单克隆抗体的一个限制性特征 人类抗鼠抗体的发展。 如果 抗体最终被修饰成一种有效的 癌症患者的抗肿瘤治疗， 人抗鼠单克隆抗体仍将是一种重要的 问题. 因此，我们启动了一项研究， 抗体，试图治疗结直肠癌患者， carcinoma. 两种人单克隆抗体16.88和28 A32 目前正在研究中。 两者都来自人类B细胞 来自用免疫的结肠直肠癌患者， 自体肿瘤细胞疫苗 这些单克隆抗体具有 用I-131进行放射性标记，并定位于肿瘤， 转移性结直肠癌患者。 14例 到目前为止，还没有人产生抗体， 施用人单克隆抗体。 然而，两名患者 已存在针对其中一种或两种的抗体 克隆抗体 这些患者未被录入 study. 尽管这些单克隆抗体被运输到 在荷瘤部位，未观察到抗肿瘤反应。

A large number of patients have been treated with murine monoclonal antibodies in several phase I and II studies. In general, the anti-tumor effects of this therapy have been disappointingly few. It has been demonstrated, however, that antibodies can reach the site of the tumor and strain the tumor cells specifically. In general it appears that monoclonal antibodies in and of themselves as currently being used are not effective tools in the treatment of cancer. One limiting feature of the use of murine monoclonal antibodies has been the development of human antimouse antibodies. If antibodies ultimately are modified to become an effective antitumor treatment for patients with cancer, the development of human antimouse monoclonal antibodies will still be a significant problem. We, therefore, initiated a study using human monoclonal antibodies in an attempt to treat patients with colorectal carcinoma. Two human monoclonal antibodies 16.88 and 28A32 are currently being studied. Both are derived from human B cells from patients with colorectal carcinoma immunized with an autologous tumor cell vaccine. These monoclonal antibodies have been radiolabeled with I-131 and have localized to tumors in patients with metastatic colorectal carcinoma. Of 14 patients treated so far, none have developed antibodies against the administered human monoclonal antibody. However, two patients had pre-existing antibody directed against either or both monoclonal antibodies. These patients were not entered on the study. Despite trafficking of these monoclonal antibodies to the tumor-bearing site, no antitumor responses have been observed.